Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Dianthus Therapeutics (DNTH) Non-Current Assets: 2017-2024

Historic Non-Current Assets for Dianthus Therapeutics (DNTH) over the last 6 years, with Dec 2024 value amounting to $93.1 million.

  • Dianthus Therapeutics' Non-Current Assets rose 145.09% to $163.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $163.6 million, marking a year-over-year increase of 145.09%. This contributed to the annual value of $93.1 million for FY2024, which is 4664.79% up from last year.
  • According to the latest figures from FY2024, Dianthus Therapeutics' Non-Current Assets is $93.1 million, which was up 4,664.79% from $2.0 million recorded in FY2023.
  • In the past 5 years, Dianthus Therapeutics' Non-Current Assets ranged from a high of $93.1 million in FY2024 and a low of $1.1 million during FY2022.
  • Moreover, its 3-year median value for Non-Current Assets was $2.0 million (2023), whereas its average is $32.0 million.
  • Data for Dianthus Therapeutics' Non-Current Assets shows a peak YoY soared of 4,664.79% (in 2024) over the last 5 years.
  • Dianthus Therapeutics' Non-Current Assets (Yearly) stood at $1.1 million in 2022, then surged by 81.43% to $2.0 million in 2023, then spiked by 4,664.79% to $93.1 million in 2024.